Thu, Jul 10, 2014, 10:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • extractofhuman extractofhuman Jan 5, 2012 10:11 PM Flag

    Non Event

    ..."you can bet Jefferies did significant due diligence"..... You are aware that Jefferies sold 600 million of MF Global bonds--3 months before MF Global blew up? Some due diligence there. Never assume that someone else has done the hard work.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hope and hype are all these people have.

      All these shysters trying to get people to believe there will be a huge ramp up of production before Phase 2 trials end, when their last Phase 3 trial killed people. Ludicrous!

      • 2 Replies to hailstorm_catapult
      • sorry folks, but the fact that jefferies is involved,in my opinion
        does not bode well,ask avnr investors how they feel about them.



        glta rw

      • Mr. Hailstorm, I respect folks who have opposite views, and I can often learn from them if they have a rational argument and not silly immature comments. I am long this stock based on the potential of Ganetespib, period. I don't care about your macro economic views of the world, many which I agree with. I don't care about the failure of a past Synta clinical program, as the best biotech's and big pharma's of the world have had duds. I don't care about you mocking and marginalizing the insider buying of one director.

        I care about Ganetespid, as most longs do. So I would be very interested if you can provide a serious, detailed and scientific explanation on why you think the Ganetespid program would fail. Thanks.

 
SNTA
4.375-0.205(-4.48%)Jul 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.